Pfizer’s metastatic breast cancer medicine has been named the “Best Pharmaceutical Product” at the 10th Annual Prix Galien USA Awards in New York, among the industry’s most prestigious accolades.
Prix Galien USA recognizes exceptional pharmaceutical innovations that have improved health around the globe. Pfizer’s metastatic breast cancer medicine took the top prize among a category of 22 products.
Pfizer’s metastatic breast cancer drug is the first cyclin-dependent kinase inhibitor approved by the FDA. Cyclin-dependent kinases are important regulators of cell growth. Pfizer’s first-in-class medicine works by interfering with the kinases and stopping cancer cells from dividing and growing.